Transgenic mice carrying the entire polyomavirus (Py) early region consistently develop both vascular and bone tumors. This tumor spectrum represents a subset of the tumors found in mice infected with Py and an expansion of the vascular tumor spectrum seen in Py middle T antigen (MT) transgenic mice (V. L. Bautch, S. Toda, J. A. Hassell, and D. Hanahan, Cell 51:529-538, 1987). Transgenic mice of three independent lineages develop these pathologies, and mice of individual lineages also develop lymphangiomas and fibrosarcomas. All tumors are of mesenchymal origin, and all tumor tissues express the Py transgene. Some unaffected tissues, including the testes of mice of all lineages, also express the Py transgene. The number of transgene expression sites in mice of a given lineage correlates with the severity and latency of the tumor phenotype in these animals. Analysis of transgene transcripts indicates that RNAs for Py large T antigen (LT), MT, and small T antigen (ST) are present in both tumors and testes of transgenic mice. The ratio of LT RNA to MT and ST RNAs, however, is higher in testes than in tumors and other unaffected tissues, indicating that tissue-specific differences in the relative amounts of the alternatively spliced Py RNAs exist. The finding that some sites of Py transgene expression are susceptible to tumor formation while other expressing tissues such as testes are refractory to tumorigenesis suggests that mechanisms of viral pathogenesis are influenced by a tissue specificity in the effects of the Py early region. Viral pathogenesis is a complex process involving virushost cell interactions that can lead to tumor formation (37). One classic model for the study of viral pathogenesis is the interactions of polyomavirus (Py) with its natural host, the mouse (for reviews, see references 13 and 19). Py causes tumors in a range of tissues in newborn and immunocompromised mice. The tumor spectrum of Py includes epithelial tumors such as parotid gland tumors and mammary adenocarcinomas as well as mesenchymal tumors such as osteosarcomas and fibrosarcomas (for a review, see reference 9). Recently, viral strain differences in the tumor spectrum of Py were documented, and the Py strains fit two broad categories: (i) epithelial and mesenchymal tumors and (ii) mesenchymal tumors only (10, 16).
Viral pathogenesis is a complex process involving virushost cell interactions that can lead to tumor formation (37) . One classic model for the study of viral pathogenesis is the interactions of polyomavirus (Py) with its natural host, the mouse (for reviews, see references 13 and 19) . Py causes tumors in a range of tissues in newborn and immunocompromised mice. The tumor spectrum of Py includes epithelial tumors such as parotid gland tumors and mammary adenocarcinomas as well as mesenchymal tumors such as osteosarcomas and fibrosarcomas (for a review, see reference 9). Recently, viral strain differences in the tumor spectrum of Py were documented, and the Py strains fit two broad categories: (i) epithelial and mesenchymal tumors and (ii) mesenchymal tumors only (10, 16) .
The tumorigenic potential of Py is localized to the early region of the Py genome that encodes three different gene products (6) . These proteins are translated from a single primary transcript via alternative splicing (38) . Py large T antigen (LT) is a 100-kDa protein required for viral replication, Py middle T antigen (MT) is a 56-kDa protein with transforming activity (24, 39) , and Py small T antigen (ST) is a 22-kDa protein that promotes growth in some assays (28) . Cell culture experiments have shown that Py LT is also capable of immortalizing primary cells to continuous growth in culture (32) and that Py MT can confer a transformed phenotype to cultured cells. Moreover, these proteins can cooperate with each other and with other oncogenes to fully transform primary cells in culture (31, 33) . Thus, Py provides a convenient system for studying both the separate and the concerted actions of viral oncogenes in vivo.
Studies of oncogene action in transgenic mice have shown that both viral and cellular oncogene expression is correlated with tumor formation and that many oncogenes show a cell-type specificity in their action in vivo (for reviews, see * Corresponding author. references 7, 21, and 22) . Surprisingly, a number of papovavirus early regions that show a broad spectrum of expression in cell culture have a restricted expression and tumor profile in transgenic mice. For example, simian virus 40 early region expression is restricted to a few tissue sites and leads to predominantly choroid plexus tumors (5, 29) . Likewise, the JC virus and BK virus early regions show restricted expression in transgenic mice, leading to tumors that recapitulate their tropism in humans (36) . A Py early region promoter and enhancer linked to a reporter gene showed low-level expres- sion in a number of tissues (25) .
To study the effects of the Py early region oncogenes in vivo, we have generated transgenic mice carrying Py early region cDNAs linked to the Py early region regulatory sequences. Transgenic mice carrying the Py MT cDNA showed restricted expression patterns and developed vascular endothelial cell tumors exclusively, transgenic mice carrying the Py LT cDNA developed pituitary tumors with a long latency, and transgenic mice carrying the Py ST cDNA developed no detectable pathology (2, 2a, 3) . Here we report that transgenic mice carrying an intact Py early region that is replication defective consistently develop vascular and bone tumors, and with some frequency they also develop lymphangiomas and fibrosarcomas. These tumors are of mesenchymal-cell origin, and they represent an expanded tumor spectrum relative to that of Py cDNA-carrying mice.
MATERIALS AND METHODS
DNA constructions. The Py DNA was of the Al strain (30) , and it has been modified from the wild-type genome as described elsewhere to make Px13 DNA (3) . Briefly, the Py genome was linearized at the BamHI site in the late region and inserted into the pML2 vector (26 Generation and identification of transgenic mice. Px13 DNA was linearized at a Sail site in the plasmid sequences, extracted with phenol and chloroform, ethanol precipitated, and suspended in injection buffer as described elsewhere (3). Microinjection was into F2 embryos from a mating of B6D2F1 mice, and all procedures were as described previously (23) with modifications (3). Positive offspring were identified by Southern blot analysis of genomic DNA extracted from tail clips and hybridized to 32P-labeled nicktranslated Px13 DNA as described previously (1, 3) . Positive mice were mated with B6D2F1 mice to establish germ line transmission. Subsequent matings of positive transgenic mice were usually male transgenic mice to B6D2F1 females, and positive offspring were identified by dot blot analysis as described elsewhere (35) .
RNA isolation and analysis. Total RNA was isolated from mouse organs by a modification of the hot-phenol method (35) as described before (3). The RNA protection assay was performed by a modification of a previously described method (27) . A 32P-labeled antisense RNA probe was synthesized from PxXP64 DNA with SP6 polymerase. The probe was hybridized with 10 or 20 ,ug of total RNA from mouse tissues, and the mixture was digested with RNases A and T1. The protected RNA products were analyzed by 8 M urea-5% polyacrylamide gel electrophoresis and autoradiography as described previously (3) . The polymerase chain reaction (PCR) was performed by a modification of the method described by Saiki et al. (34) . cDNA was synthesized from total RNA as described elsewhere (17) 
RESULTS
Generation of transgenic mice. To determine the effects of the Py early region gene in transgenic mice, the linearized Py early region DNA illustrated in Fig. 1 Three of the eight founder mice transmitted the Py transgene to progeny, and the transmission ratios indicate that the Py-3 founder mouse was mosaic for the transgene in his germ line while the other two founder mice were probably heterozygous for the transgene. Two founders with pathology, Py-1 and Py-2, were probably mosaic because they died without transmitting the transgene to progeny. However, all of the founders that transmitted the transgene developed pathology. All three of these founder mice developed vascular hemangiomas, while two of three founders developed bone tumors and one of three founders developed lymphangiomas ( Table 1) .
Pathology of Py transgenic mouse lineages. The three lineages Py-3, Py-4, and Py-5 were derived from the three founder Py transgenic mice that transmitted the transgene to offspring, and their characteristics are documented in Table  2 . In general, the pathology of progeny was similar to the pathology of the respective founder mouse, although some differences were noted. For example, examination of multiple progeny showed the presence of bone tumors in Py-3 mice and the occasional presentation of a fibrosarcoma in Py-3 and Py-5 mice. Transgenic mice of all lineages developed pathology that was eventually fatal to the animal, and there were both similarities and differences among the phenotypes of the three lineages. Mice of all lineages developed vascular and bone tumors, indicating that this tumor profile They often showed visible signs of lymphangioma formation at 4 to 6 weeks of age, and they quickly developed large cystlike structures in the inguinal and axial areas. At approximately 8 to 12 weeks of age, multiple small blood-filled structures became visible on the ears, tail, and paws. These mice became moribund several days prior to death, although the exact cause of death was not determined. At necropsy, all Py-4 mice showed multiple large cysts filled with a straw-colored liquid at various sites including inguinal, axial, cervical, retroperitoneal, and subcutaneous sites (Fig. 2C) . These cysts were sometimes intimately associated with blood-filled cystic structures. Most mice showed evidence of multiple small blood-filled structures on the ears and tail ( Fig. 2A) , and males had small blood-filled areas on the testes that resembled vascular tumors. In general, the bloodfilled tumors were not found at other sites in Py-4 mice. All Py-4 mice also had an obvious thickening of the skull that gave it a white, solid appearance rather than a thin, opalescent appearance (Fig. 2B) .
Py-3 and Py-5 transgenic mice showed a less consistent, less dramatic set of symptoms than did Py-4 mice. Mice of these lineages usually developed a single tumor, and the tumors were vascular, bony, or fatty. Mice with vascular tumors usually had a tumor in one or two of several sites that included most organs. The tumors most often were larger than the blood-filled sacs of the Py-4 mice and in both appearance and location resembled the hemangiomas of Py MT mice (3) . A subset of mice of both lineages developed hind-limb paralysis at some point. Although tumors were not detected macroscopically in all mice with this symptom, in about 80% of these mice, tumors were found at autopsy, and they were always bony tumors associated with the lower spinal cord (Fig. 2D) . Thus, the hind-limb paralysis is probably a result of spinal-cord pinching by the bone tumors. These tumors were also occasionally seen on the rib cage, in association with joints, and in the skull. On rare occasions, mice of both lineages also developed large solid and fatty protuberant tumors at random locations. Death was most likely due either to hemorrhage or to wasting from paralysis or a large tumor.
The microscopic analysis of tumor tissues is presented in Fig. 3 . Histological study of the blood-filled tumors of Py-4 mice showed small blood-filled sacs interspersed among normal tissue structures, as shown in the photomicrograph of a Py-4 ear (Fig. 3A) . A higher magnification of this type of tumor showed that the caverns were lined by one or a few layers of thin, elongated cells (Fig. 3B ). This histological picture is consistent with the identification of these tumors as vascular endothelial cell tumors, and they resemble the hemangiomas described in Py MT mice (3).
The microscopic examination of a Py-3 bone tumor showed tumor tissue adjacent to normal rib muscle tissue, with no sign of invasion (Fig. 3C) . Upon visual examination, the skull thickenings of the Py-4 mice appeared multifocal and seemed to involve more healthy bone tissue than did the bone tumors of the Py-3 and Py-5 mice. At the microscopic level, however, the Py-4 skull had tumors that resembled the Py-3 bone tumor (Fig. 3D ). Higher magnification of the tumor tissue revealed individual atypical cells surrounded by extracellular material (inset, Fig. 3D ). This histology is characteristic of osteogenic sarcomas, tumors of osteoblast cells that produce bone matrix.
The fluid-filled cysts found in all Py-4 mice consisted of irregular open spaces with some leukocytes and with expansion of both the lining and surrounding fatty tissue (Fig. 3E) . The association of some of the cysts with sites of major lymph nodes, and the presence of straw-colored fluid and of leukocytes rather than erythrocytes all contribute to the identification of these structures as lymphangiomas. The large fatty tumors that occasionally were found in Py-3 and Py-5 mice consisted of relatively undifferentiated cells that appeared to be of mesenchymal origin, which is consistent with the identification of these tumors as fibrosarcomas (Fig.  3F) .
Expression analysis. To determine the expression pattern of the transgene in the Py transgenic mice, RNA extracted from healthy tissues and from tumors of mice of each of the three lineages was analyzed. The Py early region transgene (Fig. 1) (Fig. 4 and Table 3 ). The major transcription initiation site in the transgene is 5' of major viral transcription start sites (compare controls in Fig. 4, lanes 1 to 3 [3] ). Thus, the presence of a protected band of 424 bases results from the presence of MT, ST, and/or unspliced RNAs, while a protected band of 349 bases results from the presence of LT RNA. All tumors and some unaffected tissues, including the testes of all lineages, expressed the Py transgene (Fig. 4 and ' Tumor represents skull osteosarcoma and lymphangioma for Py-4, hemangioma and fibrosarcoma for Py-3, and osteosarcoma for Py-5.
Mice of the Py-4 lineage (Fig. 4 , lanes 6 to 8 and 8A, and Table 3 ) had the greatest number of unaffected sites that expressed the transgene, including the liver. In contrast, RNAs from mice of the Py-3 lineage (Fig. 4, lanes 9 to 11, and Table 3 ) did not show protected fragments indicating liver expression of the transgene (Fig. 4, lane 9) . However, RNAs from Py-3 testes, an unaffected tissue, and an abnormal Py-3 skull that probably carried a tumor were positive for the protected fragments (Fig. 4, lanes 10 and 11) . Mice of the Py-5 lineage showed an expression pattern similar to that of the Py-3 mice, with transgene expression restricted to tumors and testes (Fig. 4, lane 12 , and Table 3 ).
It was possible to determine the relative levels of Py transgene RNA expression in a comparative manner. The amount of total RNA, the amount of reaction mixture loaded on the gel (see the legend to Fig. 4 (Fig. 4, lanes 8 protected fragment only in testis RNA is consistent (data not shown). The relative ratio of the different Py RNAs thus seems to be regulated differently in testes than in tumors and other tissue sites of expression.
To determine the exact pattern of expression of each of the Py RNAs, we employed a sensitive PCR assay to cDNAs synthesized from RNAs of various tumors and tissues. One set of primers (oligonucleotides Px5 and Px8; see Fig. 1 for locations) gives PCR products unique to templates for unspliced, MT, and ST RNAs, and a second set of primers (oligonucleotides Px2 and Px3; see Fig. 1 for locations) allowed for detection of a PCR product specific to LT RNA.
The results of the PCR are shown in Fig. 5 . Lanes 1 to 5 of the PCR analysis are the same RNA samples as were analyzed by RNA protection in lanes 6 to 10 of Fig. 4 .
Analysis of Py MT and ST RNAs (Fig. 5A) revealed that all sites of transgene expression were positive for PCR products of 189 and 175 bp that were specific to ST and MT RNA, respectively. An additional prominent PCR product of 238 bp could result from an unspliced RNA template, or it could result from DNA contamination of the RNA samples. It was determined that approximately 50% of the 238-bp PCR product resulted from a template that is destroyed by alkaline conditions (data not shown), indicating that unspliced RNA and contaminating DNA both contribute templates to this product. This finding is consistent with the results of RNA protection analysis with a probe that covers the MT and ST splice sites and gives a unique protected fragment with unspliced RNA. In this analysis, more than 90% of the "unspliced" protected fragment was alkaline sensitive, and the relative amount of this fragment did not vary among different RNAs (data not shown).
LT RNA analysis (Fig. SB) showed that a subset of tissues and all tumors was positive for an LT RNA-specific PCR product of 414 bp. All testes that showed an LT RNAspecific protected fragment by RNA protection analysis produced the LT-specific PCR product (Fig. SB, lanes 2 and 5, and Table 3 ). The tumors and Py-4 liver, however, did not have detectable LT-specific protected fragments by RNA protection, yet they also produced an LT-specific PCR product. This discrepancy probably results from the high sensitivity of the PCR reaction and the lack of background in this assay. The PCR reaction was not quantitated, so absolute amounts of LT RNA were not determined, but it is likely that Py transgenic-mouse tumors contain very low but detectable levels of LT RNA.
The expression analysis using both assays was extended to other tissues, and the results are documented in Table 3 . Several results were confirmed and extended by this complete analysis. First, as noted above, all tumors and testes from mice of all lineages expressed the Py transgene. Second, other unaffected organs were sites of transgene expression in a lineage-dependent manner. For example, Py-4 mice showed transgene expression in the liver, spleen, kidney, and brain, and Py-5 mice showed expression only in the kidney. Third, some sites of expression, such as brain tissues of Py-4 and Py-3 mice, were negative by RNA protection analysis but positive by the more sensitive PCR analysis. Finally, expression of the LT RNA was not detectable in some sites where expression of ST and MT RNAs was documented, such as spleens and kidneys of Py-4 mice. It thus appears that both lineage-specific differences in expression patterns and tissue-specific differences in the relative amounts of the different Py mRNAs contribute to a complex expression pattern of the Py early region transgene.
DISCUSSION
The analysis of these transgenic mice shows that the Py early region is tumorigenic in transgenic mice. Five members (62.5%) of a group of eight founder mice had detectable pathology that was fatal to the animals in all cases. Three lineages of Py transgenic mice were established in which the Py early region transgene was passed through the germ line to progeny. All mice that carried the transgene developed fatal tumors. Mice of all lineages developed vascular and bone tumors, indicating that this tissue specificity for Py transgene action is a result of the cis-acting sequences associated with the transgene.
The tumors induced by the Py transgene are found exclusively in tissues of mesenchymal origin. In addition to the J. VIROL. (4, 10, 16) . The noncoding regions of the different Py genomes were found to influence the frequency of tumor formation, but the primary determinant of tissue tropism for viral tumorigenesis was localized to a single amino acid polymorphism in the VP1 capsid protein encoded by the late region (14) .
The The Py early region transgene was expressed in the tumors that developed as well as in some unaffected organs. The major site of expression was the testis, and all testes of males of all lineages expressed the Py transgene. Other nontumor sites of expression, such as the liver, spleen, kidney, and brain, varied with lineage. Thus, mice of the Py-4 lineage showed the broadest spectrum of tissues expressing the transgene, and they also developed the most severe pathology and died at a very young age. It is likely, therefore, that the Py-4 transgene integrated in a chromosomal site that promotes widespread expression early in life, whereas the Py-3 and Py-5 integrations may have occurred in a chromosomal context that is more restrictive of expression. These differences in expression of the same transgene among different lineages have been documented, and they sometimes reflect temporal patterns of tumorigenesis (20, 40) .
The Py early region transgene can produce three different mRNAs by alternative splicing, and these RNAs encode the three early region proteins Py LT, MT, and ST (37) . Differences in the relative amounts of the three RNAs were found in transgenic mouse tissues, and specifically, the relative amount of Py LT RNA was higher in testes than in all other sites of expression. This finding suggests that regulation is at the level of alternative splicing, although it is formally possible that differential RNA stability leads to higher relative levels of Py LT RNA in testes. Splicing of Py LT RNA, which has a unique 5' donor site and a 3' acceptor site common to Py ST, thus appears to be favored in testes relative to other sites of expression. In contrast, the coexpression of Py MT and ST at all expression sites is consistent with the reported cooperativity between the two different 3' acceptor sites in vitro (18) . Other alternatively spliced genes such as that for calcitonin-CGRP show a tissue-regulated splicing pattern that is reconstituted in transgenic mice (8) .
Regardless of how differential expression is effected, the low levels of Py LT RNA 
